Erlizumab
| Monoclonal antibody | |
|---|---|
| Type | F(ab')2 fragment |
| Source | Template:Infobox drug/mab source |
| Target | CD18 |
| Identifiers | |
| CAS Number | 211323-03-4 |
| ATC code | none |
Erlizumab, also known as rhuMAb, is a recombinant humanized monoclonal antibody that was an experimental immunosuppressive drug. Erlizumab was developed by Genentech under a partnership with Roche to treat heart attack, stroke, and traumatic shock.[1]
Mechanism of action
The drug works by blocking a growth factor in blood vessels.[2] Specifically, erlizumab targets CD18 and an LFA-1 integrin.[3] Erlizumab was meant to stop lymphocyte movement into inflamed tissue, thereby reducing tissue damage.[4]
Clinical trials
Genentech started clinical trials on the drug in October 1996.[5] During clinical trials, six patients suddenly started coughing up blood, and four of them later died.[2] In June 2000, preliminary phase II clinical trial results showed that erlizumab did not meet Genentech's goals.[1] Genentech's primary goal was for the drug to increase blood flow to the heart within 90 minutes of administering the medicine.[4]
Other anti-CD18 drugs
Multiple companies have tried to develop anti-CD18 drugs, but none of them have been successful.[4] Among them are Icos's rovelizumab (LeukArrest), and two drugs developed by Protein Design Labs (PDL) and Centocor.[4] Although trials in humans have not gone well, the research of CD18 drugs in animals has been encouraging.[4] It is thought that the experimental medicines are affecting the lymphocyte adhesion pathway in humans in unintended ways.[4] One hypothesis is that the endothelial cell barrier function fails when blood supply is low for a prolonged time in humans.[6] If this is true, the drug is not able to stop lymphocyte movement into inflamed tissue.[6]
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />- ↑ 1.0 1.1 "Genentech Announces Phase II Trial of Experimental Anti-CD18 Antibody Did Not Meet Its Primary Objectives". Business Wire. June 16, 2000. Retrieved January 29, 2009.
- ↑ 2.0 2.1 Altman, Lawrence (May 30, 2000). "THE DOCTOR'S WORLD; In Search of Surprises as Cures for Cancer". The New York Times. Retrieved January 29, 2009.
- ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- ↑ 4.0 4.1 4.2 4.3 4.4 4.5 Dove, Alan (2000). "CD18 trials disappoint again". Nature Biotechnology. 18 (8): 817–8. doi:10.1038/78412. PMID 10932141.
- ↑ "Genentech Reports 1996 Third Quarter Results". Genentech. October 21, 1996. Retrieved January 31, 2009.
- ↑ 6.0 6.1 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- Pages with script errors
- Articles which use infobox templates with no data rows
- Drugs that are a monoclonal antibody
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- 2Fix
- Monoclonal antibodies
